Legal & General Group PLC Novo Cure LTD Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Novo Cure LTD stock. As of the latest transaction made, Legal & General Group PLC holds 184,412 shares of NVCR stock, worth $5.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

184,412

Previous 184,412 -0.0%

Holding current value

$5.82 Million

Previous $2.88 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $189,833 - $283,837	12,161 Added 7.06%	184,412 $2.88 Million
Q2 2024 Aug 14, 2024	BUY	$11.83 - $24.05 $37,607 - $76,454	3,179 Added 1.88%	172,251 $2.95 Million
Q1 2024 May 14, 2024	SELL	$12.42 - $17.29 $291,075 - $405,208	-23,436 Reduced 12.17%	169,072 $2.64 Million
Q4 2023 Feb 15, 2024	BUY	$11.13 - $15.78 $152,525 - $216,249	13,704 Added 7.66%	192,508 $2.87 Million
Q3 2023 Nov 14, 2023	SELL	$16.15 - $42.35 $5.38 Million - $14.1 Million	-332,824 Reduced 65.05%	178,804 $2.89 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $2.82 Million - $5.78 Million	70,096 Added 15.88%	511,628 $21.2 Million
Q1 2023 May 15, 2023	SELL	$56.44 - $118.81 $3.43 Million - $7.21 Million	-60,687 Reduced 12.08%	441,532 $26.6 Million
Q4 2022 Feb 14, 2023	SELL	$63.98 - $85.37 $2.26 Million - $3.02 Million	-35,375 Reduced 6.58%	502,219 $36.8 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $2.54 Million - $3.35 Million	-37,372 Reduced 6.5%	537,594 $40.8 Million
Q2 2022 Aug 22, 2022	BUY	$56.6 - $89.9 $2.72 Million - $4.32 Million	48,051 Added 9.12%	574,966 $40 Million
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $2.23 Million - $3.13 Million	-37,022 Reduced 6.56%	526,915 $43.7 Million
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $167,578 - $272,281	2,232 Added 0.4%	563,937 $42.3 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $832,241 - $1.39 Million	7,164 Added 1.29%	561,705 $65.3 Million
Q2 2021 Aug 12, 2021	BUY	$130.4 - $225.58 $4.55 Million - $7.87 Million	34,904 Added 6.72%	554,541 $123 Million
Q1 2021 May 17, 2021	BUY	$124.11 - $190.17 $27.8 Million - $42.5 Million	223,653 Added 75.56%	519,637 $68.7 Million
Q4 2020 Feb 12, 2021	BUY	$112.16 - $174.14 $22.7 Million - $35.3 Million	202,811 Added 217.67%	295,984 $51.2 Million
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $164,513 - $315,452	2,834 Added 3.14%	93,173 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $1.77 Million - $2.3 Million	30,964 Added 52.15%	90,339 $5.36 Million
Q1 2020 May 14, 2020	BUY	$57.05 - $95.75 $127,677 - $214,288	2,238 Added 3.92%	59,375 $4.01 Million
Q4 2019 Feb 13, 2020	BUY	$68.3 - $93.8 $458,224 - $629,304	6,709 Added 13.3%	57,137 $4.82 Million
Q3 2019 Nov 13, 2019	BUY	$61.86 - $97.8 $631,528 - $998,440	10,209 Added 25.38%	50,428 $3.77 Million
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $313,061 - $468,850	7,415 Added 22.6%	40,219 $2.54 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $19,559 - $34,345	612 Added 1.9%	32,804 $1.58 Million
Q4 2018 Feb 15, 2019	BUY	$28.72 - $52.63 $119,618 - $219,203	4,165 Added 14.86%	32,192 $1.08 Million
Q3 2018 Nov 20, 2018	BUY	$32.0 - $52.4 $9,632 - $15,772	301 Added 1.09%	28,027 $1.47 Million
Q2 2018 Aug 10, 2018	BUY	$19.85 - $32.0 $142,979 - $230,496	7,203 Added 35.1%	27,726 $868,000
Q1 2018 May 17, 2018	SELL	$19.3 - $23.65 $64,114 - $78,565	-3,322 Reduced 13.93%	20,523 $447,000
Q4 2017 Feb 13, 2018	BUY	$16.3 - $21.9 $388,673 - $522,205	23,845	23,845 $482,000

Others Institutions Holding NVCR

# of Institutions

263

Shares Held

77M

Call Options Held

1.17M

Put Options Held

318K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.31B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Novo Cure LTD Transaction History